Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Diffuse Midline Glioma, H3 K27-Altered · CancerIndex

Cancers
Neoplasm
Neoplasm by Morphology
Neuroepithelial, Perineurial, and Schwann Cell Neoplasm
Neuroepithelial Neoplasm
Glioma
Diffuse Glioma
Diffuse Midline Glioma
Diffuse Midline Glioma, H3 K27-Altered

Molecular Subtype

Diffuse Midline Glioma, H3 K27-Altered

CI-CAN-00007581Explore in graph →

20 active trials15 evidence items

NCIt: C185368
OncoTree: DMG
DOID: 0080684

Overview
Statistics
Survival
Genomics
Variants & evidence15
Drugs2
Trials31
Research
Rankings
Sources & provenance

Data completeness3 / 7 dimensions

Epidemiology (no data yet)
Survival (no data yet)
Trials (data present)
Literature (data present)
Genomics (no data yet)
Evidence (data present)
Therapies (no data yet)

Computed from entity_counters.completeness · refreshed after each connector run

Definition

What this entity is

A diffuse midline glioma characterized by H3 K27 alteration and usually either a histone H3 K27M mutation, an EGFR mutation, or aberrant overexpression of EZHIP. The prognosis is poor.

Definition text as published by ncit-evsProvenance

Source: NCI Thesaurus (NCIt)
Dataset: NCI Thesaurus
Version: 26.08e
Retrieved: Sep 8, 2026
Layer: raw (as published)
Evidence: expert curation
License: CC BY 4.0
Run: ING-NCITEVS-20260908-000001

Open at source Curated

Data updated 22 days agoSource updated 26.08e

Taxonomy

Position in the hierarchies

Several hierarchies coexist; edges are listed per hierarchy type with their source.

Parents

ncit

Diffuse Midline GliomaSubtype

oncotree

Pediatric-Type Diffuse High-Grade GliomaSubtype

Children (5)

ncit

Adult Diffuse Midline Glioma, H3 K27-Altered1 sub
Childhood Diffuse Midline Glioma, H3 K27-Altered
Diffuse Midline Glioma, EGFR-Mutant
Diffuse Midline Glioma, H3 K27M-Mutant1 sub
Diffuse Midline Glioma with EZHIP Overexpression

6 descendants in total; counters on this page aggregate over all of them.

Anatomy

Anatomical sites

Nervous SystemC3268

Record

Identity

CancerIndex ID: CI-CAN-00007581
Entity type: Molecular Subtype
Malignant: Yes
Solid / hematologic: Solid tumor
Pediatric relevant: Not flagged
Rare cancer: Unknown (no incidence data yet)
Hierarchy depth: 7
Classification version: 26.08e
Semantic types: Neoplastic Process
Status: Active
Record updated: 2026-09-08

Coverage

Data completeness

Trials (all / active)

31 / 20

Publications (all / 5y)

52 / 52

Evidence items

15

Genes / variants

4 / 10

Drugs (any / approved)

2 / 0

Genomic cohorts

0

Epidemiology / survival obs.

0 / 0

Data updated 10 minutes agoSource updated unknowncounters aggregate over descendants

Names

Synonyms (1)

Diffuse Midline Glioma, H3 K27-Alteredsynonym · OncoTree

CancerIndex is a research and information platform. It does not diagnose and does not recommend treatment.

Key figures

At a glance

Each figure carries its unit, period and source; ranks link to "Why this rank?".

US deaths18,523countUnited States · 2024 · both sexes · all agescdc-wonderObservedrank #9 of 31 (USA · both sexes · all ages · 2024 · top-level cancers)figures shown for Malignant Central Nervous System Neoplasm (registry level) — open Malignant Central Nervous System Neoplasm
US new cases22,882countUnited States · 2023 · both sexes · all agescdc-uscsObservedrank #17 of 32 (USA · both sexes · all ages · 2023 · top-level cancers)figures shown for Malignant Central Nervous System Neoplasm (registry level) — open Malignant Central Nervous System Neoplasm
US age-standardized mortality4.4per 100,000United States · 2024 · both sexes · all ages · 2000 U.S. Std. Populationcdc-wonderObservedrank #8 of 23 (USA · both sexes · all ages · 2024 · top-level cancers)figures shown for Malignant Central Nervous System Neoplasm (registry level) — open Malignant Central Nervous System Neoplasm
Active trials20countcurrent registry status · entity + descendantsclinicaltrialsComputedrank #436 of 1,654 (World · both sexes · all ages · latest · all malignant entities)
Recruiting trials15countstatus RECRUITING · entity + descendantsclinicaltrialsComputedrank #370 of 1,284 (World · both sexes · all ages · latest · all malignant entities)
Curated evidence items15countaccepted CIViC items · entity + descendantscivicComputedrank #170 of 492 (World · both sexes · all ages · latest · all malignant entities)
Publications, last 12 months15countPubMed records · stored query · 12-month windowpubmedComputedrank #825 of 2,294 (World · both sexes · all ages · latest · all malignant entities)
Genomic cohorts0countopen GDC projects · entity + descendantsgdcComputednot in a current ranking snapshot

Data updated 10 minutes agoSource updated unknownregistry figures: cdc-uscs · latest year available per metric · counters aggregate over descendants